Sphingolipids in Neuroinflammation

Handbook of Experimental Pharmacology

Volumn 216, Issue , 2013, Pages 421-430

  Davies, Laura ^a   Fassbender, Klaus ^a   Walter, Silke ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Multiple Sclerosis; Neuroinflammation; Neuroinflammatory diseases; Sphingolipids

Indexed keywords

CERAMIDE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN ISCHEMIA; BRAIN MALARIA; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GUILLAIN BARRE SYNDROME; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SPINAL CORD INJURY; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; ENCEPHALITIS; METABOLISM; NERVE CELL; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; ENCEPHALITIS; HUMANS; NEURONS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

MLCS; MLOWN;

EID: 84892867432     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1511-4_21     Document Type: Article

References (70)

1. Avota E, Gulbins E, Schneider-Schaulies S (2011) DC-SIGN mediated sphingomyelinaseactivation and ceramide generation is essential for enhancement of viral uptake in dendritic cells. PLoS Pathog 7(2):e1001290
2. Barth BM, Gustafson SJ, Kuhn TB (2012) Neutral sphingomyelinase activation precedes NADPHoxidase- dependent damage in neurons exposed to the proinflammatory cytokine tumor necrosis factor-?. Neurosci Res 90:229-242
3. Ben-David O, Futerman HA (2010) The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromol Med 12:341-350
4. Borri PF, Op den Velde WM, Hooghwinkel GJ, Bruyn GW (1967) Biochemical studies in Huntington's chorea. VI. Composition of striatal neutral lipids, phospholipids, glycolipids, fatty acids, and amino acids. J Neurol 17(2):172-178
5. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P (2010) Fingolimod (FTY729): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:833-897
6. Cameron NE, Cotter MA (2008) Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets Jan 9(1):60-67
7. Choi JW, Chun J (2013) Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta 1831(1):20-32
8. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108(2):751-756
9. Cohen JA, Chun J (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69:759-777
10. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402-415
11. Crutcher KA, Gendelman HE, Kipnis J, Perez-Polo JR, Perry VH, Popovich PG, Weaver LC (2006) Debate: "is increasing neuroinflammation beneficial for neural repair?". J Neuroimmune Pharmacol 1(3):195-211
12. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 52(4):448-457
13. Cuzzocrea S, Deigner HP, Genovese T, Mazzon E, Esposito E, Crisafulli C, Di Paola R, Bramanti P, Matuschak G, Salvemini D (2009) Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. Shock 31(6):634-644
14. Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, Rami A, Huwiler A, Pfeilschifter J (2009) The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 389(2):251-256
15. Di Pardo A, Maglione V, Alpaugh M, Horkey M, Atwal RS, Sassone J, Ciammola A, Steffan JS, Fouad K, Truant R, Sipione S (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci USA 109(9):3528-3533
16. Edwards JL, Vincent AM, Cheng HT, Feldman EL (2008) Diabetic neuropathy: mechanisms to management. Pharmacol Ther 120(1):1-34
17. Etminan M, Gill S, Samii A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-Analysis of observational studies. BMJ 327(7407):128
18. Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, Plomp JJ, Willison HJ (2012) Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 122(3):1037-1051
19. Finney CAM, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, Oravecz T, Liles WC, Kain KC (2011) S1P is associated with protection in human and experimental cerebral malaria. Mol Med 17(7-8):717-725
20. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T (2009) FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain damage. Brain Pathol 19:254-266
21. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47
22. Gassert E, Avota E, Harms H, Krohne G, Gulbins E, Schneider-Schaulies S (2009) Induction of membrane ceramides: a novel strategy to interfere with T lymphocyte cytoskeletal reorganisation in viral immunosuppression. PLoS Pathog 5(10):e1000623
23. Geisler FH, Dorsey FC, Coleman WP (1991) Recovery of motor function after spinal-cord injury-A randomized, placebo-controlled trial with GM-1ganglioside. N Engl J Med 324(26):1829-1838
24. Geisler FH, Coleman WP, Grieco G, Poonian D, Sygen Study Group (2001) The Sygen multicenter acute spinal cord injury study. Spine 26(24 Suppl):S87-S98
25. Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G, Mancardi GL, Battistini L, Uccelli A (2003) Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol 73(5):584-590
26. Gulbins E, Lee PL (2006) Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 290:11-26
27. Haggiag S, Steiner-Birmanns B, Wirguin I, Sicsic C, Brenner T, Steiner I (2004) Seroconversion of anti-GM1 antibodies in patients with amyotrophic lateral sclerosis. J Neurol 63(4):755-756
28. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH (2010) Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41(2):368-374
29. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, Lee S, Jong A (2011) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylationregulated kinase 3 (DYRK3). J Biol Chem 286(40):34761-34769
30. Hughes RA, Cornblath DR (2005) Guillain-Barré syndrome. Lancet 366(9497):1653-1666
31. In t'Veld BA, Ruitenberg A, Hofman A (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521
32. Jana A, Pahan K (2010) Sphingolipids in multiple sclerosis. Neuromolecular Med 12(4):351-361
33. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
34. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30(2):131-156
35. Kim S, Steelman AJ, Zhang Y, Kinney HC, Li J (2012) Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol 22(1):41-57
36. Kobayashi Y, Kiguchi N, Maeda T, Ozaki M, Kishioka S (2012) The critical role of spinal ceramide in the development of partial sciatic nerve ligation-induced neuropathic pain in mice. Biochem Biophys Res Commun 421(2):318-322
37. Köhne AS, Stettner M, Jangouk P, Dehmel T, Hartung HP, Lehmann HC, Kieseier BC (2012) Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Effect of Fingolimod on Schwann cells. Arch Neurol 2:1-10
38. Kumar A, Negi G, Sharma SS (2012) Suppression of NF-?B and NF-?B regulated oxidative stress and neuroinflammation by BAY 11-7082 (I?B phosphorylation inhibitor) in experimental diabetic neuropathy. Biochimie 94(5):1158-1165
39. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Exp Med 201(2):233-240
40. McColl BW, Allan SW, Rothwell NJ (2007) Systemic inflammation and stroke: aetiology, pathology and targets for therapy. Biochem Soc Trans 35:1163-1165
41. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22:799-809
42. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24(4):574-576
43. Myers RR, Shubayev VI (2011) The ology of neuropathy: an integrative review of the role of neuroinflammation and TNF-? axonal transport in neuropathic pain. J Peripher Nerv Syst 16(4):277-286
44. Nayak D, Huo Y, Kwang WXT, Pushparaj PN, Kumar SD, Ling EA, Dheen ST (2010) Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 166:132-144
45. Novgorodov SA, Gudz TI (2011) Ceramide and mitochondria in ischemic brain injury. Int J Biochem Mol Biol 2(4):347-361
46. Orr CF, Rowe DB, Halliday GM (2002) An inflammatory review of Parkinson's disease. Prog Neurobiol 68(5):325-340
47. Pannu R, Won JS, Khan M, Singh AK, Singh I (2004) A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma- mediated inducible nitric oxide synthase gene expression: implications for neuroinflammatory diseases. J Neurosci 24(26):5942-5954
48. Phong MC, Gutwein P, Kadel S, Hexel K, Altevogt P, Linderkamp O, Brenner B (2003) Molecular mechanisms of L-selectin-induced co-localization in rafts and shedding. Biochem Biophys Res Commun 300:563-569
49. Ransohoff RM (2012) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31:711-721
50. Rao JS, Kellom M, Kim HW, Rapoport SI, Reese EA (2012) Neuroinflammation and synaptic loss. Neurochem Res 37(5):903-910
51. Ribatti D, Nico B, Crivellato E, Artico M (2006) Development of the blood-brain barrier: a historical point of view. Anat Rec 289B:3-8
52. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9(6):429-430
53. Rosenman SJ, Ganji AA, Tedder TF, Gallatin WM (1993) Syn-capping of human T lymphocyte adhesion/activation molecules and their redistribution during interaction with endothelial cells. J Leukoc Biol 53:1-10
54. Schneider JS, Sendek S, Daskalakis C, Cambi F (2010) GM1 ganglioside in Parkinson's disease: results of a five year open study. J Neurol Sci 292(1-2):45-51
55. Soeda S, Tsuji Y, Ochiai T, Mishima K, Iwasaki K, Fujiwara M, Yokomatsu T, Murano T, Shibuya S, Shimeno H (2004) Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochem Int 45(5):619-626
56. Stoffel B, Bauer P, Nix M, Geres K, Stoffel W (1998) Ceramide-independent CD28 and TCR signaling but reduced IL-2 secretion in T cells of acid sphingomyelinase-deficient mice. Eur J Immunol 28:874-880
57. Streit WJ, Mrak RE, Griffin WST (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1(1):14
58. Strong K, Mathers C, Bonita R (2007) Preventing stroke: saving lives around the world. Lancet Neurol 6(2):182-187
59. Tajima O, Egashira N, Ohmi Y (2009) Reduced motor and sensory functions and emotional response in GM3-only mice: emergence from early stage of life and exacerbation with aging. Behav Brain Res 198:74-82
60. Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, Lakeman K, Dijkstra CD, Van Der Valk P, Reijerkerk A, Alewijnse AE, Peters SLM, De Vries HE (2010) Sphingosine 1-Phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 58:1465-1476
61. Van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van Het Hof B, Kooij G, Reijerkerk A, Dijkstra C, van van der Valk P, van Horssen J, de Vries HE (2012) Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 124(3):397-410
62. Wang J, Doré S (2007) Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 27:894-908
63. Witton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150(8):963-976
64. Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL (2008) Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 17:2257-2264
65. Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW (2011) Mice lacking major brain gangliosides develop parkinsonism. Neurochem Res 36(9):1706-1714
66. Yang Y, Xu J, Niu Y, Bromberg JS, Ding Y (2008) T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol 181(12):8700-8710
67. Yu RK, Nakatani Y, Yanagisawa M (2009) The role of glycosphingolipid metabolism in the developing brain. J Lipid Res 50(Suppl):S440-S445
68. Yu RK, Tsai YT, Ariga T (2012) Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res 37(6):1230-1244
69. Yuki N, Hartung HP (2012) Guillain-Barré syndrome. N Engl J Med 366(24):2294-2304
70. Zappia M, Crescibene L, Bosco D, Arabia G, Nicoletti G, Bagalà A, Bastone L, Napoli ID, Caracciolo M, Bonavita S, Di Costanzo A, Gambardella A, Quattrone A (2002) Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106(1):54-57